KRW 25200.0
(0.0%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 13.96 Billion KRW | 11.09% |
2022 | 12.57 Billion KRW | 6.39% |
2021 | 11.81 Billion KRW | 7.31% |
2020 | 11.01 Billion KRW | 34.86% |
2019 | 8.16 Billion KRW | 44.91% |
2018 | 5.63 Billion KRW | 87.95% |
2017 | 2.99 Billion KRW | 84.48% |
2016 | 1.62 Billion KRW | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q1 | 3.43 Billion KRW | -26.55% |
2024 Q2 | 3.43 Billion KRW | -0.11% |
2023 FY | 13.96 Billion KRW | 11.09% |
2023 Q2 | 2.9 Billion KRW | -3.59% |
2023 Q3 | 3.36 Billion KRW | 15.96% |
2023 Q4 | 4.67 Billion KRW | 38.86% |
2023 Q1 | 3.01 Billion KRW | -29.91% |
2022 Q2 | 2.93 Billion KRW | 14.26% |
2022 FY | 12.57 Billion KRW | 6.39% |
2022 Q4 | 4.29 Billion KRW | 55.08% |
2022 Q3 | 2.77 Billion KRW | -5.48% |
2022 Q1 | 2.56 Billion KRW | -25.18% |
2021 Q3 | 2.27 Billion KRW | 0.0% |
2021 Q4 | 3.43 Billion KRW | 50.78% |
2021 FY | 11.81 Billion KRW | 7.31% |
2020 FY | 11.01 Billion KRW | 34.86% |
2019 FY | 8.16 Billion KRW | 44.91% |
2018 FY | 5.63 Billion KRW | 87.95% |
2017 FY | 2.99 Billion KRW | 84.48% |
2016 FY | 1.62 Billion KRW | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
HLB Pharmaceutical Co., Ltd | 135.95 Billion KRW | 89.726% |
CMG Pharmaceutical Co., Ltd. | 93.9 Billion KRW | 85.126% |
Celltrion Pharm, Inc. | 388.79 Billion KRW | 96.407% |
Huons Global Co., Ltd. | 758.37 Billion KRW | 98.158% |
DongKook Pharmaceutical Co., Ltd. | 730.99 Billion KRW | 98.089% |
Enzychem Lifesciences Corporation | 76.03 Billion KRW | 81.63% |
Humedix Co., Ltd. | 152.27 Billion KRW | 90.827% |
Boditech Med Inc. | 134.21 Billion KRW | 89.593% |
EuBiologics Co., Ltd. | 69.36 Billion KRW | 79.863% |
Huons Co., Ltd. | 552 Billion KRW | 97.47% |
BNC Korea Co., Ltd. | 80.99 Billion KRW | 82.755% |
AptaBio Therapeutics Inc. | 323.86 Million KRW | -4212.862% |